2018 - 2017 - 2016 - 2015 - 2014 - 2013 - 2012 - 2011 - 2010 - 2009

CBIS Set to Partner and Power the New iPhone APP, "The Joey Network", Just Released by Mieko Hester-Perez, SAB Member, Providing Patients and Families a Wealth of Autism Resources and Cannabis Treatment Options

CBIS Set to Partner and Power the New iPhone APP, "The Joey Network", Just Released by Mieko Hester-Perez, SAB Member, Providing Patients and Families a Wealth of Autism Resources and Cannabis Treatment Options

COLORADO SPRINGS, CO--(Marketwired - Mar 1, 2016) - Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, is proud to announce its newest Scientific Advisory Board appointee, Mieko Hester-Perez, launched "The Joey Network" -- the iPhone APP for autism patients, families and physicians considering cannabis treatments -- on this significant day of her son's birthday.

"We are thrilled! This is the first cannabis and autism-centered APP made available for patients and families worldwide, and now it can be downloaded on the iPhone for free. 'The Joey Network' is designed to allow users to research the latest in autism and cannabis treatments," said Ms. Hester- Perez. "The APP provides key resources to any patient seeking medical cannabis as a potential treatment for autism, from legal referrals to product recommendations and even parental consultations. As well, you can join 'The Joey Network' to share stories, ask questions, and give feedback with other users, and even reach out for help via a phone call.

"Initially the beta version is launched on iPhone, subsequent roll-outs on other popular online APP platforms will come after we receive patient feedback, add more interactive research, and infuse the Cannabis Science footprint and research into the APP. Partnering with Cannabis Science will bring additional targeted research and industry updates, and will provide an international influence to 'The Joey Network'. This partnership will create more exposure for all the Company's research, while at the same time creating more relevant and rich content for patients to instantly access. Please download it today and comment so we can hear your valuable feedback," stated Ms. Hester- Perez.

Ms. Hester-Perez first gained international attention in 2009, when she brought public her autistic son's success with medical cannabis by giving interviews on some of the country's largest media outlets, such as, FOX Morning News, The Doctors Show, The Dr. Juan Rivera Show, NBC syndicates, CBS, Good Morning America with Diane Sawyer, and "Inspiring Parents" on ABC's 20/20 special segments. Understanding the needs of autistic patients and families, she created "The Joey Network" designed to provide relevant and valuable resources to empower families and individuals going through their own personal experiences.

"We are very proud of Mieko for directly providing her incredible knowledge to potentially millions of people who are affected by autism. She is aggregating important research for patients and/or caregivers, which can be difficult to find. Her passion for helping people find the right treatment is truly admirable and we are honored to have her on board to help push the cause," said Cannabis Science President & CEO, Raymond C. Dabney.

About Cannabis Science, Inc.

Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.

Forward-Looking Statements

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a 'safe harbor' for forward looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company are detailed from time to time in the company's reports filed with the Securities and Exchange Commission.